Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance

por Inagaki, Nobuya, Nangaku, Masaomi, Sakata, Yasushi, Sasaki, Kazuyo, Mori-Anai, Kazumi, Iwasaki, Tomohisa, Hamada, Koume
Publicado 2021

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan

por Kadowaki, Takashi, Inagaki, Nobuya, Watada, Hirotaka, Sasaki, Kazuyo, Mori-Anai, Kazumi, Iwasaki, Tomohisa, Teranishi, Tatsuki
Publicado 2022

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐b...

por Wada, Takashi, Mori‐Anai, Kazumi, Takahashi, Akiko, Matsui, Takahiro, Inagaki, Masaya, Iida, Mitsutaka, Maruyama, Ken, Tsuda, Hidetaka
Publicado 2022

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin a...

por Wada, Takashi, Mori‐Anai, Kazumi, Kawaguchi, Yutaka, Katsumata, Hideyuki, Tsuda, Hidetaka, Iida, Mitsutaka, Arakawa, Kenji, Jardine, Meg J
Publicado 2021